Latest Pharma and Biotech News
Biotechnology
11 December 2024 San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
Today's issue
Refine Search
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello announced that its European regulatory filing for Acarizax (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 European Union (EU countries via a type II variation procedure. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Biotechnology
Daiichi Sankyo has announced plans to invest 1.1 billion renminbi ($150 million) to build a new manufacturing facility for antibody-drug conjugates (ADCs) in Shanghai's Zhangjiang area. 12 December 2024
Pharmaceutical
Eli Lilly has announced Phase III results for imlunestrant, its investigational oral selective estrogen receptor degrader (SERD), in breast cancer. 12 December 2024
Biotechnology
California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, has announced the closing of a $120 million Series C financing round. 12 December 2024
Biotechnology
Utah, USA-based privately-held biotech Halia Therapeutics has announced promising top-line data resulting in the advancement to the second stage of its Phase II clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk myelodysplastic syndromes (LR-MDS). 12 December 2024
Pharmaceutical
Neuraxpharm Group, a privately-held specialty pharma focused on central nervous system (CNS) disorders, and Greek drugmaker Pharmathen, a developer and supplier of long-acting injectable (LAI) therapies, have announced a strategic alliance. 12 December 2024
Biotechnology
US clinical-stage biotech Q32 Bio saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed update on its research pipeline, that analysts called “messy.” 12 December 2024
Pharmaceutical
Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) for the combination of its Orpathys (savolitinib) and AstraZeneca’s Tagrisso (osimertinib). 12 December 2024
Pharmaceutical
Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced an overview of its strategy and new organizational structure at its Investor Update 2024. 12 December 2024
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
All news
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello announced that its European regulatory filing for Acarizax (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 European Union (EU countries via a type II variation procedure. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Biotechnology
Daiichi Sankyo has announced plans to invest 1.1 billion renminbi ($150 million) to build a new manufacturing facility for antibody-drug conjugates (ADCs) in Shanghai's Zhangjiang area. 12 December 2024
Pharmaceutical
Eli Lilly has announced Phase III results for imlunestrant, its investigational oral selective estrogen receptor degrader (SERD), in breast cancer. 12 December 2024
Biotechnology
California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, has announced the closing of a $120 million Series C financing round. 12 December 2024
Biotechnology
Utah, USA-based privately-held biotech Halia Therapeutics has announced promising top-line data resulting in the advancement to the second stage of its Phase II clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk myelodysplastic syndromes (LR-MDS). 12 December 2024
Pharmaceutical
Neuraxpharm Group, a privately-held specialty pharma focused on central nervous system (CNS) disorders, and Greek drugmaker Pharmathen, a developer and supplier of long-acting injectable (LAI) therapies, have announced a strategic alliance. 12 December 2024
Biotechnology
US clinical-stage biotech Q32 Bio saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed update on its research pipeline, that analysts called “messy.” 12 December 2024
Pharmaceutical
Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) for the combination of its Orpathys (savolitinib) and AstraZeneca’s Tagrisso (osimertinib). 12 December 2024
Pharmaceutical
Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced an overview of its strategy and new organizational structure at its Investor Update 2024. 12 December 2024
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze